News & Investors

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 29, 2016
- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients   -- Top-line data expected in first quarter of 2017  - STAMFORD, Conn., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities design...
Nov 22, 2016
STAMFORD, Conn., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will parti...
Nov 8, 2016
STAMFORD, Conn., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will prese...
Nov 3, 2016
-  Currently enrolling three late stage studies with CR845 totaling over 900 patients  -   -  Top line data expected in 1H 2017  - -  Conference call today at 4:30 p.m. ET  - STAMFORD, CONN., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemi...
Oct 31, 2016
STAMFORD, Conn., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of two posters at Kidney Week 2016, t...
Oct 27, 2016
STAMFORD, Conn., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live ...
Oct 12, 2016
STAMFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced its participation at two upcoming medical meetings, bo...
Oct 3, 2016
Webcast to be held Thursday, October 6, 2016 at 11:00 a.m. ET STAMFORD, Conn., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today a...
Sep 29, 2016
STAMFORD, Conn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will host an industry symposium titled "Movin...
Sep 15, 2016
Trial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients Top-line data expected in first half of 2017 STAMFORD, Conn., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed...
Sep 2, 2016
STAMFORD, Conn., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will pres...
Sep 1, 2016
Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain managementCompany to present data from Phase 2 chronic osteoarthritis pain and human abuse liability trials of CR845 in poster sessions STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company fo...
Aug 5, 2016
STAMFORD, Conn., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will prese...
Aug 4, 2016
- Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain - - Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritus - - Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016 - - Conference call today at 4:30 p.m. ET - STAMFORD, Conn....
Jul 28, 2016
STAMFORD, Conn., July 28, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live ...
= add release to Briefcase